PT  - JOURNAL ARTICLE
AU  - Dami A. Collier
AU  - Anna De Marco
AU  - Isabella A.T.M. Ferreira
AU  - Bo Meng
AU  - Rawlings Datir
AU  - Alexandra C. Walls
AU  - Steven A. Kemp S
AU  - Jessica Bassi
AU  - Dora Pinto
AU  - Chiara Silacci Fregni
AU  - Siro Bianchi
AU  - M. Alejandra Tortorici
AU  - John Bowen
AU  - Katja Culap
AU  - Stefano Jaconi
AU  - Elisabetta Cameroni
AU  - Gyorgy Snell
AU  - Matteo S. Pizzuto
AU  - Alessandra Franzetti Pellanda
AU  - Christian Garzoni
AU  - Agostino Riva
AU  - The CITIID-NIHR BioResource COVID-19 Collaboration
AU  - Anne Elmer
AU  - Nathalie Kingston
AU  - Barbara Graves
AU  - Laura E McCoy
AU  - Kenneth GC Smith
AU  - John R. Bradley
AU  - Nigel Temperton
AU  - Lourdes Ceron-Gutierrez L
AU  - Gabriela Barcenas-Morales
AU  - The COVID-19 Genomics UK (COG-UK) consortium
AU  - William Harvey
AU  - Herbert W. Virgin
AU  - Antonio Lanzavecchia
AU  - Luca Piccoli
AU  - Rainer Doffinger
AU  - Mark Wills
AU  - David Veesler
AU  - Davide Corti
AU  - Ravindra K. Gupta
TI  - SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies
AID  - 10.1101/2021.01.19.21249840
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.19.21249840
4099  - http://medrxiv.org/content/early/2021/02/15/2021.01.19.21249840.short
4100  - http://medrxiv.org/content/early/2021/02/15/2021.01.19.21249840.full
AB  - Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) transmission is uncontrolled in many parts of the world, compounded in some areas by higher transmission potential of the B1.1.7 variant now seen in 50 countries. It is unclear whether responses to SARS-CoV-2 vaccines based on the prototypic strain will be impacted by mutations found in B.1.1.7. Here we assessed immune responses following vaccination with mRNA-based vaccine BNT162b2. We measured neutralising antibody responses following a single immunization using pseudoviruses expressing the wild-type Spike protein or the 8 amino acid mutations found in the B.1.1.7 spike protein. The vaccine sera exhibited a broad range of neutralising titres against the wild-type pseudoviruses that were modestly reduced against B.1.1.7 variant. This reduction was also evident in sera from some convalescent patients. Decreased B.1.1.7 neutralisation was also observed with monoclonal antibodies targeting the N-terminal domain (9 out of 10), the Receptor Binding Motif (RBM) (5 out of 31), but not in neutralising mAbs binding outside the RBM. Introduction of the E484K mutation in a B.1.1.7 background to reflect newly emerging viruses in the UK led to a more substantial loss of neutralising activity by vaccine-elicited antibodies and mAbs (19 out of 31) over that conferred by the B.1.1.7 mutations alone. E484K emergence on a B.1.1.7 background represents a threat to the vaccine BNT162b.Competing Interest StatementA.D.M., J.B., D.P., C.S.F., S.B., K.C., N.S., E.C., G.S., S.J., A.L., H.W.V., M.S.P., L.P. and D.C. are employees of Vir Biotechnology and may hold shares in Vir Biotechnology. H.W.V. is a founder of PierianDx and Casma Therapeutics. Neither company provided funding for this work or is performing related work. D.V. is a consultant for Vir Biotechnology Inc. The Veesler laboratory has received a sponsored research agreement from Vir Biotechnology Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. RKG has received consulting fees from UMOVIS Lab, Gilead and ViiV.Funding StatementThis research was supported by the National Institute for Health Research Cambridge Biomedical Research Centre. RKG is supported by a Wellcome Trust Senior Fellowship in Clinical ScienceAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the East of England Cambridge Central Research Ethics Committee 17 EE 0025.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available from the corresponding author on request